Syngene Intl.

Which are the latest news on Syngene Intl.?

Are Syngene International Ltd latest results good or bad?

Syngene International Ltd's latest results are concerning, showing a net loss of ₹9.00 crores in Q1 FY27, a significant decline from a profit of ₹147.90 crores in the previous quarter, alongside a 15.84% drop in revenue and a low operating margin of 12.34%. These trends indicate serious operational challenges and raise concerns about the company's future sustainability and growth.

The latest results for Syngene International Ltd are concerning and indicate a significant decline in profitability. In Q1 FY27, the company reported a net loss of ₹9.00 crores, marking its first quarterly loss in recent history. This is a stark contrast to the profit of ₹147.90 crores reported in the previous quarter (Q4 FY26).<BR><BR>Revenue also took a hit, declining by 15.84% year-on-year to ₹736.00 crores, which is the lowest quarterly revenue figure in over two years. The operating margin collapsed to 12.34%, down from 23.60% a year earlier, representing the lowest operating margin recorded in the last twelve quarters. This sharp decline in margins raises questions about the company's cost management and pricing power in a competitive environment.<BR><BR>Additionally, the return on equity (ROE) stands at a weak 7.41%, indicating poor capital efficiency. The operational challenges are compounded by a significant year-on-year decline in operating profit, which fell by 56.01% to ₹90.80 crores.<BR><BR>Overall, these results reflect a troubling trend for Syngene, suggesting that the company is facing serious challenges that could impact its future sustainability and growth. Investors should be cautious and closely monitor the company's performance moving forward.

Should I buy, sell or hold Syngene International Ltd?

Why is Syngene International Ltd falling/rising?

As of 30-Jul, Syngene International Ltd's stock price is falling, currently at 398.85, reflecting a change of -14.8 (-3.58%). The stock has significantly underperformed, with a year-to-date decline of -38.72% and a drastic drop in financial performance, including a -95.0% reduction in profit after tax, leading to weak growth prospects and a high price-to-book value compared to peers.

As of 30-Jul, Syngene International Ltd's stock price is falling, currently at 398.85, reflecting a change of -14.8 (-3.58%). The stock has recently hit a new 52-week low of Rs. 375.5, indicating significant downward pressure. Today, it opened with a loss of -7.4% and reached an intraday low of Rs. 375.5, which is a decline of -9.22%. <BR><BR>The company's performance has been consistently poor, with a year-to-date decline of -38.72% and a staggering -44.77% drop over the past year. This underperformance is stark when compared to the benchmark Sensex, which has only declined by -8.56% during the same period. Additionally, the stock has underperformed against the benchmark in each of the last three annual periods, with a -51.64% return over the last three years.<BR><BR>Financial results have also contributed to the stock's decline. The company reported a significant fall in net sales of -28.99% and a drastic reduction in profit after tax (PAT) of -95.0% compared to the previous four-quarter average. This has led to a very low return on capital employed (ROCE) of 10.12% and a low operating profit to interest ratio of 9.46 times, indicating financial strain.<BR><BR>Despite having high institutional holdings at 39.83%, which typically suggests a level of confidence in the company's fundamentals, the overall financial health and growth prospects appear weak. The stock is trading at a premium compared to its peers, with a price-to-book value of 3.3, which is considered expensive given its low return on equity (ROE) of 7.4. <BR><BR>In summary, the combination of poor financial results, significant declines in stock price, and consistent underperformance against benchmarks are the primary reasons for the falling stock price of Syngene International Ltd.

How big is Syngene Intl.?

As of 10th June, Syngene International Ltd has a market capitalization of 18,127.00 Cr, with recent net sales of 3,738.70 Cr and a net profit of 316.70 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Syngene International Ltd has a market capitalization of 18,127.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 3,738.70 Cr, while the sum of Net Profit for the same period is 316.70 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 4,726.80 Cr, and Total Assets amount to 6,766.50 Cr.

Who are in the management team of Syngene Intl.?

The management team of Syngene International includes Kiran Mazumdar Shaw (Chairperson), Jonathan Hunt (Managing Director & CEO), and several independent directors such as Vinita Bali and Paul Blackburn, among others, bringing diverse expertise to the company.

The management team of Syngene International includes the following key members:<BR><BR>1. **Kiran Mazumdar Shaw** - Chairperson<BR>2. **Catherine Patricia Rosenberg** - Director<BR>3. **Paul Frederick Blackburn** - Independent Director<BR>4. **Vijay Kuchroo** - Independent Director<BR>5. **Jonathan Hunt** - Managing Director & CEO<BR>6. **Vinita Bali** - Lead Independent Director<BR>7. **Priyadarshnini Mahapatra** - Company Secretary & Compliance Officer<BR>8. **Sharmila Karve** - Independent Director<BR>9. **Carl Decicco** - Director<BR>10. **Kush Parmar** - Independent Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the Syngene Intl.?

Syngene Intl.'s peers include Dr Lal Pathlabs, Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Health, Thyrocare Tech., Suven Life Sciences, Vimta Labs, and Krsnaa Diagnost. Syngene Intl. has good management risk and an excellent capital structure, but its 1-year return is the lowest among peers at -31.13%.

Peers: The peers of Syngene Intl. are Dr Lal Pathlabs, Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, and Thyrocare Tech. Average management risk is noted at Indegene, Vimta Labs, and Krsnaa Diagnost., while Below Average management risk is seen at Suven Life Scie. Growth is uniformly Below Average across all peers. Excellent capital structure is present at Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Average capital structure is noted at Indegene and Vimta Labs, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vijaya Diagnost. at 36.33%, while the lowest is Syngene Intl. at -31.13%. This indicates that Syngene Intl.'s 1-year return is significantly lower than that of its peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, and Krsnaa Diagnost.

What does Syngene Intl. do?

Syngene International Limited is a small-cap integrated research, development, and manufacturing services organization in the healthcare sector, reporting net sales of 1,036 Cr and a net profit of 148 Cr for the quarter ending March 2026. Key metrics include a P/E ratio of 51.00 and a market cap of INR 18,127 Cr.

Overview:<BR>Syngene International Limited is an integrated research, development, and manufacturing services organization operating in the healthcare services industry and classified as a small-cap company.<BR><BR>History:<BR>Syngene International was incorporated in an unspecified year and has maintained its status as a key player in the healthcare services sector. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,036 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 148 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 18,127 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 51.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.27%<BR>- Debt Equity: -0.17<BR>- Return on Equity: 7.41%<BR>- Price to Book: 3.72<BR><BR>Contact Details:<BR>Address: Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds Bengaluru Karnataka : 560099<BR>Tel: 91-80-68915000/67758781<BR>Email: investor@syngeneintl.com<BR>Website: http://www.syngeneintl.com

When is the next results date for Syngene International Ltd?

The next results date for Syngene International Ltd is April 29, 2026.

The next results date for Syngene International Ltd is scheduled for April 29, 2026.

Is Syngene Intl. technically bullish or bearish?

As of December 4, 2025, Syngene Intl. shows a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearishness, despite some mildly bullish signals from the weekly MACD.

As of 4 December 2025, the technical trend for Syngene Intl. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the weekly OBV also showing mild bearishness. The MACD on the weekly chart is mildly bullish, but the monthly MACD remains bearish, suggesting mixed signals across time frames. The Bollinger Bands are bearish on both weekly and monthly charts, reinforcing the bearish sentiment. Overall, while there are some mildly bullish indicators, the prevailing trend remains bearish.

How has been the historical performance of Syngene Intl.?

Syngene Intl. has shown consistent growth in net sales and operating profit from INR 1,825.60 crore in March 2019 to INR 3,642.40 crore in March 2025, although profit after tax slightly declined in 2025. Total assets and cash flow from operations have also improved significantly during this period.

Answer:<BR>The historical performance of Syngene Intl. shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Syngene Intl. has demonstrated a strong upward trend in net sales, increasing from INR 1,825.60 crore in March 2019 to INR 3,642.40 crore in March 2025. This growth is reflected in the total operating income, which also rose from INR 1,825.60 crore to INR 3,642.40 crore during the same period. The company's operating profit (PBDIT) has similarly improved, reaching INR 1,113.60 crore in March 2025, up from INR 611.90 crore in March 2019. However, profit after tax showed a slight decline from INR 510.00 crore in March 2024 to INR 496.20 crore in March 2025. The total assets of Syngene increased significantly from INR 4,040.20 crore in March 2020 to INR 6,766.50 crore in March 2025, while total liabilities also rose from INR 4,040.20 crore to INR 6,766.50 crore in the same timeframe. Cash flow from operating activities has improved, reaching INR 1,167.00 crore in March 2025, compared to INR 677.00 crore in March 2020, indicating a positive cash generation trend. Overall, Syngene Intl. has shown robust growth in revenue and operational efficiency, despite some fluctuations in net profit.

Who are the top shareholders of the Syngene Intl.?

The top shareholders of Syngene International are Biocon Limited with 52.46%, mutual funds at 17.86%, and foreign institutional investors holding 19.47%. The highest public shareholder is ICICI Prudential Innovation Fund with a 5.13% stake, while individual investors own about 5.08%.

The top shareholders of Syngene International include Biocon Limited, which holds the largest stake at 52.46%. Other significant shareholders are mutual funds, which collectively own 17.86% of the company, and foreign institutional investors (FIIs) who hold 19.47%. The highest public shareholder is ICICI Prudential Innovation Fund, with a 5.13% stake. Additionally, individual investors own about 5.08% of the shares.

What is the bonus history of the Syngene Intl.?

Syngene International Ltd announced a 1:1 bonus issue on June 11, 2019, with a record date of June 12, 2019, allowing shareholders to receive one additional share for each share held.

Syngene International Ltd has a bonus history that includes a 1:1 bonus issue announced on June 11, 2019. The record date for this bonus was June 12, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Syngene Intl. declared dividend?

Syngene International Ltd has declared a dividend of 12% (₹1.2 per share) with an ex-date of June 28, 2024. While recent total returns have been negative, longer-term performance shows positive growth.

Syngene International Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: Jun-28-2024<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -30.02%, the dividend return was 0.14%, resulting in a total return of -29.88%.<BR><BR>Over the past year, the price return was -5.96%, the dividend return was 0.34%, leading to a total return of -5.62%.<BR><BR>For the 2-year period, the price return was -12.31%, the dividend return was 0.42%, culminating in a total return of -11.89%.<BR><BR>In the last 3 years, the price return was 20.73%, the dividend return was 0.65%, resulting in a total return of 21.38%.<BR><BR>Over the past 4 years, the price return was 9.33%, the dividend return was 0.62%, leading to a total return of 9.95%.<BR><BR>In the 5-year period, the price return was 74.97%, the dividend return was 0.89%, culminating in a total return of 75.86%.<BR><BR>Overall, while Syngene International Ltd has declared a dividend, the total returns over various periods show a mixed performance, with significant declines in the short term but positive returns over the longer term.